Skip to main content

Immuneering Corporation (IMRX)

NASDAQ: IMRX · Delayed Price · USD
27.34
+0.06 (0.22%)
After-hours:Sep 21, 2021 4:06 PM EDT
27.28
2.01 (7.95%)
At close: Sep 21, 4:00 PM
Market Cap665.34M
Revenue (ttm)2.58M
Net Income (ttm)-20.07M
Shares Out24.39M
EPS (ttm)-0.82
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume165,867
Open25.14
Previous Close25.27
Day's Range23.46 - 27.41
52-Week Range16.06 - 33.99
Betan/a
Analystsn/a
Price Target43.67 (+60.1%)
Est. Earnings DateNov 15, 2021

About IMRX

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying our deep knowledge of translational bioinformatics to every stage of the drug development process. We have more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, we developed a disease-agnostic platform that enables us to utilize human ...

IndustryBiotechnology
IPO DateJul 30, 2021
CEOBenjamin J. Zeskind, Ph.D.
Employees34
Stock ExchangeNASDAQ
Ticker SymbolIMRX
Full Company Profile

Financial Performance

In 2020, Immuneering's revenue was $2.31 million, an increase of 20.41% compared to the previous year's $1.92 million. Losses were -$17.04 million, 121.0% more than in 2019.

Financial Statements

News

Immuneering Announces Inclusion in the Russell 2000® Index

CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...

1 day ago - GlobeNewsWire

5 Stocks With High Insider Buys Over Past 2 Months

According to the Insider Cluster Buys page, a Premium feature of GuruFocus, five stocks with high insider buys over the past two months are Orange County Bancorp Inc. ( OBT , Financial), FS KKR Capital ...

Other symbols:FSKGABCKKROBTSSBK
1 week ago - GuruFocus

Immuneering Reports Second Quarter 2021 Financial Results and Provides Business Updates

Recently completed upsized initial public offering raising $129.4 million in gross proceeds, providing runway into 2024

1 week ago - GlobeNewsWire

Immuneering to Participate in September Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that ...

2 weeks ago - GlobeNewsWire

Immuneering Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to ...

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of oncology and neuroscience product candidates that a...

1 month ago - GlobeNewsWire

Oncology-Focused Biotech Immuneering Jumps To Wall Street With $112M IPO

Immuneering Corp (NASDAQ: IMRX) has kept a relatively low profile since launching with $17 million back in 2019. That is until it landed another $62 million and recruited Jefferies analyst Biren Amin as...

1 month ago - Benzinga

Immuneering Announces Pricing of Upsized Initial Public Offering

Immuneering Corporation (Nasdaq: IMRX), a biopharmaceutical company advancing a robust pipeline of...

1 month ago - GlobeNewswire

Immuneering IPO Registration Document (S-1)

Immuneering Corporation has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC